567 related articles for article (PubMed ID: 15969866)
21. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Handelsman Y; Shapiro MD
Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
[TBL] [Abstract][Full Text] [Related]
22. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
Goa KL; Barradell LB; Plosker GL
Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
[TBL] [Abstract][Full Text] [Related]
23. Strategies for modifying high-density lipoprotein cholesterol: a role for nicotinic acid.
Schachter M
Cardiovasc Drugs Ther; 2005 Dec; 19(6):415-22. PubMed ID: 16453091
[TBL] [Abstract][Full Text] [Related]
24. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.
Krentz AJ
Diabetes Obes Metab; 2003 Nov; 5 Suppl 1():S19-27. PubMed ID: 14984018
[TBL] [Abstract][Full Text] [Related]
25. Nicotinic acid as a lipid-modifying drug--a review.
Julius U; Fischer S
Atheroscler Suppl; 2013 Jan; 14(1):7-13. PubMed ID: 23357134
[TBL] [Abstract][Full Text] [Related]
26. What is the most effective strategy for managing diabetic dyslipidaemia?
Reasner CA
Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442
[TBL] [Abstract][Full Text] [Related]
27. Role of fibric acid derivatives in the management of risk factors for coronary heart disease.
Després JP; Lemieux I; Robins SJ
Drugs; 2004; 64(19):2177-98. PubMed ID: 15456334
[TBL] [Abstract][Full Text] [Related]
28. Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients.
Birjmohun RS; Kastelein JJ; Poldermans D; Stroes ES; Hostalek U; Assmann G
Curr Med Res Opin; 2007 Jul; 23(7):1707-13. PubMed ID: 17588301
[TBL] [Abstract][Full Text] [Related]
29. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia.
McCormack PL; Keating GM
Drugs; 2005; 65(18):2719-40. PubMed ID: 16392885
[TBL] [Abstract][Full Text] [Related]
30. Lipid-lowering therapy in diabetes mellitus.
Niemeijer-Kanters SD; Banga JD; Erkelens DW
Neth J Med; 2001 May; 58(5):214-22. PubMed ID: 11414234
[TBL] [Abstract][Full Text] [Related]
31. Treating dyslipidemic patients with lipid-modifying and combination therapies.
Worz CR; Bottorff M
Pharmacotherapy; 2003 May; 23(5):625-37. PubMed ID: 12741437
[TBL] [Abstract][Full Text] [Related]
32. Management of hypercholesterolaemia in postmenopausal women.
Davidson MH; Maki KC; Karp SK; Ingram KA
Drugs Aging; 2002; 19(3):169-78. PubMed ID: 12027776
[TBL] [Abstract][Full Text] [Related]
33. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
34. Pharmacologic treatment of type 2 diabetic dyslipidemia.
Moon YS; Kashyap ML
Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
[TBL] [Abstract][Full Text] [Related]
35. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
[TBL] [Abstract][Full Text] [Related]
36. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Postgrad Med J; 2008 Nov; 84(997):590-8. PubMed ID: 19103817
[TBL] [Abstract][Full Text] [Related]
37. [Treatment of low HDL-cholesterol levels in the reduction of cardiovascular risk].
Stokić E; Marinkov J
Med Pregl; 2007; 60(3-4):145-50. PubMed ID: 17853726
[TBL] [Abstract][Full Text] [Related]
38. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
Isles CG; Paterson JR
QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
[TBL] [Abstract][Full Text] [Related]
39. The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin.
Ito MK
Ann Pharmacother; 2004 Feb; 38(2):277-85. PubMed ID: 14742767
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.
Boden WE
Curr Opin Cardiol; 2003 Jul; 18(4):278-85. PubMed ID: 12858126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
